Virtual Reality in COPD Exacerbation

Virtual Reality in Chronic Obstructive Pulmonary Disease: Randomized Contolled Trial

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05687396

Enrollment

Registered

2023-01-18

Start date

2022-06-01

Completion date

2024-04-22

Last updated

2026-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Exacerbation, Pulmonary Rehabilitation

Keywords

COPD, pulmonary rehabilitation, virtual reality

Brief summary

In addition to conventional pulmonary rehabilitation, virtual reality will be applied during the hospitalization period of individuals hospitalized for COPD exacerbation. It is aimed to get more efficiency from the interventions in this short time.

Detailed description

Subjects with COPD exacerbation will be divided two groups. Group-1 will exercise with a bicycle ergometer until fatigue in addition to pulmonary rehabilitation. Group-2 will do the same exercises. Subjects in Group-2 will use virtual reality simulation, which is designed as cycling in the forest while cycling. Treatment will continue until discharge. CAT score, mMRC dyspnea score, hospital anxiety and depression score and London chest daily living activity score will be examined before and after treatment.

Interventions

DEVICEvirtual reality

virtual reality designed as cycling in the forest

OTHERconventional pulmonary rehabilitation

pulmonary rehabilitation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Individuals who are in COPD exacerbation period, FEV1 \<70%, GOLD 2-3 spirometric stage, Hodkinson mental test score \> 6 and who want to participate in the study voluntarily will be included in the study.

Exclusion criteria

* If there is respiratory disease considered more significant than COPD (bronchiectasis, lung cancer requiring active therapy, or asthma), Heart failure New York Heart Association (NYHA) stage 3-4, Significant hemoptysis, surgical or non-surgical lung volume in the past 6 months Individuals with reduction procedures, Lung transplantation or pneumonectomy surgery in the last 6 months, pulmonary embolism or pulmonary edema, acute myocardial infarction, acute heart failure, vertigo, epilepsy and visual impairment will be excluded from the study.

Design outcomes

Primary

Measure	Time frame	Description
1 minute sit and stand test	5 minutes	performance
Chronic Obstructive Pulmonary Disease Assessment Test	3-7 days	The test assessts COPD symptoms, higher scores mean bad stiation
London chest activity of daily living	3-7 days	The test assessts dyspnea that occurs during daily living activities. The total score can range from 0 to 75 points, with higher values translating to greater limitation in activities of daily living.
Hospital anxiety and depression scale	3-7 days	The test has 2 subparameter as anxiety and depression. Each question in the test contains 4 options expressing frequency on a scale 0 to 3. Higher scores mean bad stiation for each parameter.
Modified Medical Research Council	3-7 days	The test has 5 options thas describe dyspnea. Higher scores mean higher dyspnea.

Countries

Turkey (Türkiye)

Contacts

PRINCIPAL_INVESTIGATORErhan Kızmaz, Msc

Pamukkale University

STUDY_DIRECTOROrçin Telli Atalay, professor